A critical overview on ticagrelor in acute coronary syndromes

Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular...

Full description

Saved in:
Bibliographic Details
Published in:QJM : An International Journal of Medicine 2013-02, Vol.106 (2), p.105-115
Main Authors: Navarese, E P, Buffon, A, Kozinski, M, Obonska, K, Rychter, M, Kunadian, V, Austin, D, De Servi, S, Sukiennik, A, Kubica, J
Format: Article
Language:English
Subjects:
Acute Coronary Syndrome - drug therapy
Acute Coronary Syndrome - physiopathology
Adenosine - administration & dosage
Adenosine - analogs & derivatives
Adenosine - pharmacology
Adenosine - therapeutic use
Aspirin - therapeutic use
Double-Blind Method
Female
Humans
Male
Platelet Aggregation Inhibitors - therapeutic use
Purinergic P2 Receptor Antagonists - administration & dosage
Purinergic P2 Receptor Antagonists - pharmacology
Purinergic P2 Receptor Antagonists - therapeutic use
Randomized Controlled Trials as Topic
Risk Assessment
Ticlopidine - analogs & derivatives
Ticlopidine - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor. However, current clinical practice has now changed with the introduction of ticagrelor, a more potent cardiovascular drug than clopidogrel, without the limitations related to clopidogrel therapy. In this review, we provide a critical overview of ticagrelor in ACS, highlight the results with ticagrelor in several subgroups of patients and discuss the future trials.
ISSN:1460-2725
1460-2393
DOI:10.1093/qjmed/hcs187